The stock of RAPT Therapeutics Inc (RAPT) has gone down by -15.46% for the week, with a -8.22% drop in the past month and a -66.27% drop in the past quarter. The volatility ratio for the week is 5.50%, and the volatility levels for the past 30 days are 5.81% for RAPT. The simple moving average for the last 20 days is -6.76% for RAPT stock, with a simple moving average of -53.77% for the last 200 days.
Is It Worth Investing in RAPT Therapeutics Inc (NASDAQ: RAPT) Right Now?
The 36-month beta value for RAPT is also noteworthy at 0.51. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RAPT is 30.64M, and at present, short sellers hold a 9.72% of that float. The average trading volume of RAPT on April 19, 2024 was 1.34M shares.
RAPT) stock’s latest price update
RAPT Therapeutics Inc (NASDAQ: RAPT)’s stock price has decreased by -1.37 compared to its previous closing price of 8.04. However, the company has seen a -15.46% decrease in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-09 that It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason.
Analysts’ Opinion of RAPT
Many brokerage firms have already submitted their reports for RAPT stocks, with UBS repeating the rating for RAPT by listing it as a “Neutral.” The predicted price for RAPT in the upcoming period, according to UBS is $10 based on the research report published on February 22, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see RAPT reach a price target of $10, previously predicting the price at $42. The rating they have provided for RAPT stocks is “Market Perform” according to the report published on February 21st, 2024.
JP Morgan gave a rating of “Neutral” to RAPT, setting the target price at $15 in the report published on February 21st of the current year.
RAPT Trading at -32.19% from the 50-Day Moving Average
After a stumble in the market that brought RAPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.01% of loss for the given period.
Volatility was left at 5.81%, however, over the last 30 days, the volatility rate increased by 5.50%, as shares sank -8.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -69.25% lower at present.
During the last 5 trading sessions, RAPT fell by -15.46%, which changed the moving average for the period of 200-days by -58.20% in comparison to the 20-day moving average, which settled at $8.47. In addition, RAPT Therapeutics Inc saw -68.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RAPT starting from Brockstedt Dirk G., who sale 898 shares at the price of $22.78 back on Jan 05 ’24. After this action, Brockstedt Dirk G. now owns 27,820 shares of RAPT Therapeutics Inc, valued at $20,456 using the latest closing price.
HO WILLIAM, the Chief Medical Officer of RAPT Therapeutics Inc, sale 2,500 shares at $21.68 during a trade that took place back on Dec 21 ’23, which means that HO WILLIAM is holding 15,020 shares at $54,200 based on the most recent closing price.
Stock Fundamentals for RAPT
The total capital return value is set at -0.84. Equity return is now at value -59.56, with -53.15 for asset returns.
Based on RAPT Therapeutics Inc (RAPT), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -14.05. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 55.46.
Currently, EBITDA for the company is -123.51 million with net debt to EBITDA at 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.41.
Conclusion
In summary, RAPT Therapeutics Inc (RAPT) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
